{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","spread":"19.88","upperLimit":"65.0","value":"21.6"},{"groupId":"OG001","lowerLimit":"2.6","spread":"31.48","upperLimit":"93.9","value":"24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Median time to event in participants who had a clinically relevant increase in serum creatinine.","dispersionType":"Full Range","groups":[{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks.","id":"OG000","title":"15 - Minute Infusion"},{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.","id":"OG001","title":"30 - Minute Infusion"}],"paramType":"MEDIAN","populationDescription":"Safety Population; enrolled patients who received at least one dose of study medication. The medians shown are only for patients who had a significant increase by 24 months.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Time to First Significant Increase in Serum Creatinine","type":"SECONDARY","unitOfMeasure":"weeks"}